The PubMed entry documents a phase 3, multicentre, randomised, double‑blind, placebo‑controlled crossover trial testing oral deucrictibant for on‑demand treatment of hereditary angioedema attacks. The citation indicates publication in Lancet (2026 Oct 24;408[10565]:1717–1731), with DOI 10.1016/S0140-6736(26)01296-1 and an electronic publication date of Oct 8, 2026. The registry-style record on PubMed lists the full title and trial design clearly. The database entry therefore verifies high‑visibility peer‑review publication and a rigorous trial framework—randomisation, blinding, placebo control, and a crossover structure—reported by the study team.
The supplied PubMed text does not include trial outcome data, numerics, or efficacy metrics. The abstract and supporting results were not present in the excerpt provided here. Investigators reported the study design and publication metadata in the record; however, any statement about clinical effect size, time to symptom relief, or statistical significance cannot be extracted from this snippet because those elements were not included in the provided source material.
The author list shown in the entry is extensive and geographically diverse. Marc A Riedl is listed as the lead author; more than 40 additional clinicians and investigators from North America, Europe, Asia, Africa, and South America are named. Site affiliations provided in the PubMed excerpt indicate participation by tertiary referral centres and academic allergy/immunology groups across multiple countries. The list includes explicit affiliations for investigators in the USA, Canada, Italy, Poland, Bulgaria, Brazil, Sweden, Argentina, Czech Republic, South Korea, Türkiye, Austria, and other nations.
The record therefore documents broad international collaboration and a multicentre operational model. The excerpt does not, however, specify the number of sites that contributed data, the geographic distribution of randomized participants, or centre‑level enrolment counts. Those methodological specifics were not included in the provided PubMed content.
The entry records a crossover design. Investigators reported a double‑blind approach with placebo control, and the phase 3 designation indicates a late‑stage therapeutic evaluation. The title itself conveys that the investigational agent was administered orally and intended for on‑demand use during angioedema attacks. That is the limit of methodological detail available in the excerpt: route of administration (oral), intended use (on‑demand treatment of attacks), and the high‑level randomised crossover architecture.
Concrete protocol items—such as dosing regimen, timing relative to attack onset, primary and secondary endpoint definitions, crossover washout intervals, inclusion and exclusion criteria, and statistical analysis plans—are not present in the supplied text. The PubMed snippet did not report these elements, so no assumptions are made here about trial conduct beyond the design descriptors explicitly provided.
The supplied PubMed content does not include trial results. There are no efficacy outcomes, no safety or adverse event summaries, no p‑values, no sample size, and no subgroup analyses in the excerpt available for review. The absence of these data in the provided record prevents any evidence‑based statement about clinical benefit, tolerability, or comparative performance versus placebo.
Because the excerpt lacks results, clinicians and decision makers should consult the full Lancet article or the publisher’s supplementary materials to obtain: primary endpoint outcome measures; time to meaningful symptom relief; responder rates; adverse event frequencies and severity; laboratory or biomarker changes if reported; and any patient‑reported outcomes employed by the study team.
The PubMed record confirms that a rigorous phase 3 crossover trial of oral deucrictibant for on‑demand treatment of hereditary angioedema attacks was completed and published. The excerpt does not report: numerical efficacy data, safety and tolerability findings, dosing and administration details, inclusion/exclusion criteria, sample size and power calculations, or statistical endpoints. Those are critical parameters for clinical interpretation and formulary decision making.
Key specific questions that remain unanswered in the provided text: what magnitude of symptom relief did investigators observe; how quickly did symptom improvement occur; what adverse events were attributed to deucrictibant; what dose was used and how often dosing was permitted during attacks; whether crossover washout was adequate to prevent carryover; and how findings varied across hereditary angioedema phenotypes and attack locations (cutaneous, abdominal, laryngeal).
Readers should retrieve the full Lancet article, supplementary appendix, or trial registry record for definitive numerical results and a complete description of methods. The PubMed excerpt establishes the study’s design, authorship, and publication provenance but does not provide the outcome data needed to guide clinical practice or policy decisions.